Physician profile
Fiona A Pathay
NPI 1992922751
$10,930.42
in general payments reported to CMS, 2019-2025
23 companies · $2,607 in 2025
The $2,607 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,465 · 2020: $1,411 · 2021: $1,506 · 2022: $1,614 · 2023: $1,123 · 2024: $1,205 · 2025: $2,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,835 · Consulting Fee: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,834.80 |
| Consulting Fee | $1,100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,221.40 | 2019-2025 | Rocklatan, Clareon, Clareon Panoptix Pro |
| Abbvie INC. | $1,945.31 | 2022-2025 | |
| Allergan, INC. | $1,527.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $583.06 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $361.41 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $239.07 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Kala Pharmaceuticals, INC. | $223.19 | 2021 | |
| Sight Sciences, INC. | $137.78 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $120.05 | 2019-2021 | |
| Oyster Point Pharma, INC. | $92.87 | 2022-2024 | Tyrvaya |
| Eyepoint US, INC. | $90.01 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $75.49 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $70.87 | 2019-2022 | |
| Genentech USA, INC. | $46.80 | 2022 | |
| Shire North American Group INC | $35.29 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $30.73 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.89 | 2019-2021 | |
| Horizon Therapeutics Plc | $22.43 | 2023 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $16.50 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $16.16 | 2019 | |
| Ocular Therapeutix, INC. | $13.26 | 2023 | Dextenza |
| Akorn, INC. | $11.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fiona Pathay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.